Jacob Johnson
Stock Analyst at Stephens & Co.
(2.91)
# 1,595
Out of 5,112 analysts
76
Total ratings
46.55%
Success rate
9.62%
Average return
Main Sectors:
Stocks Rated by Jacob Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STE STERIS | Reiterates: Overweight | $240 | $251.55 | -4.59% | 7 | Feb 6, 2025 | |
| MASS 908 Devices | Reiterates: Overweight | $6 | $5.43 | +10.50% | 4 | Jan 15, 2025 | |
| LFCR Lifecore Biomedical | Reiterates: Equal-Weight | $6 | $8.42 | -28.74% | 5 | Jan 3, 2025 | |
| AZTA Azenta | Reiterates: Overweight | $60 | $34.50 | +73.91% | 6 | Jan 2, 2025 | |
| DHR Danaher | Reiterates: Overweight | $315 | $224.35 | +40.41% | 2 | Oct 23, 2024 | |
| TMO Thermo Fisher Scientific | Initiates: Overweight | $680 | $562.39 | +20.91% | 1 | Oct 1, 2024 | |
| RGEN Repligen | Reiterates: Overweight | $170 | $157.72 | +7.79% | 4 | Jul 30, 2024 | |
| TKNO Alpha Teknova | Reiterates: Overweight | $5 | $4.65 | +7.53% | 5 | Jul 10, 2024 | |
| MXCT MaxCyte | Reiterates: Overweight | $11 | $1.52 | +623.68% | 5 | Apr 23, 2024 | |
| STVN Stevanato Group | Reiterates: Overweight | $38 | $20.52 | +85.19% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $9.44 | +80.08% | 3 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.5 | $2.15 | +16.28% | 3 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $87 | $57.10 | +52.36% | 10 | Feb 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $390 | $268.66 | +45.16% | 8 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $16 → $18 | $11.68 | +54.11% | 5 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $1.64 | +265.85% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $29 | $25.34 | +14.44% | 3 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $377 | $193.85 | +94.48% | 1 | Apr 7, 2022 |
STERIS
Feb 6, 2025
Reiterates: Overweight
Price Target: $240
Current: $251.55
Upside: -4.59%
908 Devices
Jan 15, 2025
Reiterates: Overweight
Price Target: $6
Current: $5.43
Upside: +10.50%
Lifecore Biomedical
Jan 3, 2025
Reiterates: Equal-Weight
Price Target: $6
Current: $8.42
Upside: -28.74%
Azenta
Jan 2, 2025
Reiterates: Overweight
Price Target: $60
Current: $34.50
Upside: +73.91%
Danaher
Oct 23, 2024
Reiterates: Overweight
Price Target: $315
Current: $224.35
Upside: +40.41%
Thermo Fisher Scientific
Oct 1, 2024
Initiates: Overweight
Price Target: $680
Current: $562.39
Upside: +20.91%
Repligen
Jul 30, 2024
Reiterates: Overweight
Price Target: $170
Current: $157.72
Upside: +7.79%
Alpha Teknova
Jul 10, 2024
Reiterates: Overweight
Price Target: $5
Current: $4.65
Upside: +7.53%
MaxCyte
Apr 23, 2024
Reiterates: Overweight
Price Target: $11
Current: $1.52
Upside: +623.68%
Stevanato Group
Mar 25, 2024
Reiterates: Overweight
Price Target: $38
Current: $20.52
Upside: +85.19%
Mar 13, 2024
Reiterates: Equal-Weight
Price Target: $17
Current: $9.44
Upside: +80.08%
Mar 7, 2024
Reiterates: Equal-Weight
Price Target: $2.5
Current: $2.15
Upside: +16.28%
Feb 2, 2024
Maintains: Overweight
Price Target: $92 → $87
Current: $57.10
Upside: +52.36%
Oct 27, 2023
Maintains: Overweight
Price Target: $420 → $390
Current: $268.66
Upside: +45.16%
Aug 21, 2023
Upgrades: Overweight
Price Target: $16 → $18
Current: $11.68
Upside: +54.11%
Jul 21, 2023
Reiterates: Overweight
Price Target: $6
Current: $1.64
Upside: +265.85%
Jul 17, 2023
Maintains: Overweight
Price Target: $27 → $29
Current: $25.34
Upside: +14.44%
Apr 7, 2022
Initiates: Overweight
Price Target: $377
Current: $193.85
Upside: +94.48%